MA46062A - Traitement par ascaroside de l'oesophagite à éosinophiles - Google Patents
Traitement par ascaroside de l'oesophagite à éosinophilesInfo
- Publication number
- MA46062A MA46062A MA046062A MA46062A MA46062A MA 46062 A MA46062 A MA 46062A MA 046062 A MA046062 A MA 046062A MA 46062 A MA46062 A MA 46062A MA 46062 A MA46062 A MA 46062A
- Authority
- MA
- Morocco
- Prior art keywords
- ascaroside
- treatment
- eosinophilic esophagitis
- esophagitis
- eosinophilic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662379651P | 2016-08-25 | 2016-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46062A true MA46062A (fr) | 2019-07-03 |
Family
ID=61245393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046062A MA46062A (fr) | 2016-08-25 | 2017-08-25 | Traitement par ascaroside de l'oesophagite à éosinophiles |
MA046061A MA46061A (fr) | 2016-08-25 | 2017-08-25 | Traitement ascaroside de maladies auto-immunes et inflammatoires |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046061A MA46061A (fr) | 2016-08-25 | 2017-08-25 | Traitement ascaroside de maladies auto-immunes et inflammatoires |
Country Status (5)
Country | Link |
---|---|
US (4) | US11464810B2 (fr) |
EP (2) | EP3503903A4 (fr) |
CN (1) | CN109843309A (fr) |
MA (2) | MA46062A (fr) |
WO (2) | WO2018039591A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140067029A (ko) | 2011-08-08 | 2014-06-03 | 캘리포니아 인스티튜트 오브 테크놀로지 | 식물- 및 곤충-병원성 선충을 방제하는 소형 분자 화합물 |
EP3503903A4 (fr) | 2016-08-25 | 2020-03-25 | California Institute of Technology | Traitement ascaroside de maladies auto-immunes et inflammatoires |
CN114423774A (zh) * | 2019-05-17 | 2022-04-29 | 加利福尼亚技术学院 | 蛔苷衍生物和使用方法 |
US20220264876A1 (en) * | 2019-07-08 | 2022-08-25 | Boyce Thompson Institute For Plant Research, Inc. | Compositions and methods for enhancing plant growth |
CN113475629A (zh) * | 2021-08-12 | 2021-10-08 | 广东省科学院动物研究所 | 蛔甙在制备提高S.carpocapsae All线虫产量制剂中的应用 |
CN113575770A (zh) * | 2021-08-12 | 2021-11-02 | 广东省科学院动物研究所 | 蛔甙在制备促进S.carpocapsae All感染期线虫恢复发育制剂中的应用 |
CN113796460B (zh) * | 2021-08-19 | 2023-07-18 | 云南省烟草公司玉溪市公司 | 蛔甙在制备促进H.indica LN2感染期线虫恢复发育制剂中的应用 |
CN113728978A (zh) * | 2021-08-19 | 2021-12-03 | 云南省烟草公司玉溪市公司 | 蛔甙在制备H.bacteriophora H06感染期线虫恢复发育制剂中的应用 |
WO2023212362A1 (fr) * | 2022-04-29 | 2023-11-02 | Ascribe Bioscience Inc. | Libération modifiée d'ascarosides |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1018396A (en) | 1911-08-07 | 1912-02-20 | Oley L Ledington | Culvert-mold. |
TW327125B (en) | 1994-02-07 | 1998-02-21 | Merck & Co Inc | Composition and method for protecting against pine exhausted |
WO1996019920A1 (fr) | 1994-12-27 | 1996-07-04 | Pfizer Pharmaceuticals Inc. | Compositions utilisees pour traiter les infections des arbres par les nematodes |
AU770042B2 (en) | 1998-12-18 | 2004-02-12 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
DE10163602A1 (de) | 2001-12-21 | 2003-07-10 | Alpha Biocare Gmbh Gebaeude 26 | Mittel mit Nematoden und Plathelminthen zur Behandlung allergischer Erkrankungen |
KR100700884B1 (ko) | 2002-11-14 | 2007-03-29 | 백융기 | 약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법 |
KR100556335B1 (ko) | 2004-02-05 | 2006-03-03 | 정만길 | 6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과 |
KR20070011561A (ko) | 2004-05-11 | 2007-01-24 | 바이엘 크롭사이언스 엘피 | 흰개미 방제방법 |
DE102006056544A1 (de) | 2006-11-29 | 2008-06-05 | Bayer Cropscience Ag | Insektizide Wirkstoffkombinationen (Formononetin+Insektizide) |
EP2063711A1 (fr) | 2007-03-01 | 2009-06-03 | Basf Se | Melanges actifs pesticides comprenant des composes aminothiazoline |
US8318146B1 (en) | 2008-02-01 | 2012-11-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Ascarosides as nematode sex pheromones |
EP2247603B1 (fr) | 2008-02-12 | 2016-09-28 | Dow AgroSciences LLC | Compositions pesticides |
KR20090088496A (ko) | 2008-02-15 | 2009-08-20 | 연세대학교 산학협력단 | 6-(3,6-디데옥시-α-L-아라비노-헥소피라노실옥시)헵타노익산 유도체 및 그 제조 방법 |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
KR101210553B1 (ko) | 2010-06-09 | 2012-12-10 | 연세대학교 산학협력단 | 신규한 당지질 유도체 화합물 및 이를 함유하는 혈관평활근세포 이상 증식 억제용 조성물 |
US9567361B2 (en) | 2011-05-13 | 2017-02-14 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
KR20140067029A (ko) * | 2011-08-08 | 2014-06-03 | 캘리포니아 인스티튜트 오브 테크놀로지 | 식물- 및 곤충-병원성 선충을 방제하는 소형 분자 화합물 |
BR112014003008A2 (pt) | 2011-08-08 | 2017-02-21 | Boyce Thompson Intitute For Plant Res | "compostos e métodos de modificação de comportamento de um nemátodo |
WO2013039872A1 (fr) | 2011-09-12 | 2013-03-21 | Tufts Medical Center | Compositions et procédés pour le traitement de maladies inflammatoires de l'intestin |
WO2014151648A1 (fr) * | 2013-03-15 | 2014-09-25 | Coronado Biosciences, Inc. | Traitement d'une maladie auto-immune au moyen de parasites helminthiques |
US10136595B2 (en) | 2013-03-15 | 2018-11-27 | Boyce Thompson Institute For Plant Research, Inc. | Compositions and methods for modulating immunity in plants |
EP2967052B1 (fr) * | 2013-03-15 | 2019-12-25 | Boyce Thompson Institute for Plant Research Inc. | Compositions et procédés pour moduler l'immunité chez les végétaux |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
EP3503903A4 (fr) | 2016-08-25 | 2020-03-25 | California Institute of Technology | Traitement ascaroside de maladies auto-immunes et inflammatoires |
CN114423774A (zh) | 2019-05-17 | 2022-04-29 | 加利福尼亚技术学院 | 蛔苷衍生物和使用方法 |
WO2020247480A1 (fr) | 2019-06-03 | 2020-12-10 | Holoclara, Inc. | Compositions et méthodes d'administration de microbiote de mammifère |
-
2017
- 2017-08-25 EP EP17844507.8A patent/EP3503903A4/fr active Pending
- 2017-08-25 US US16/327,670 patent/US11464810B2/en active Active
- 2017-08-25 CN CN201780061366.1A patent/CN109843309A/zh active Pending
- 2017-08-25 WO PCT/US2017/048665 patent/WO2018039591A1/fr unknown
- 2017-08-25 WO PCT/US2017/048672 patent/WO2018039593A1/fr unknown
- 2017-08-25 MA MA046062A patent/MA46062A/fr unknown
- 2017-08-25 EP EP17844508.6A patent/EP3503904A4/fr active Pending
- 2017-08-25 MA MA046061A patent/MA46061A/fr unknown
- 2017-08-25 US US16/327,659 patent/US11077151B2/en active Active
-
2021
- 2021-07-30 US US17/390,096 patent/US20220016182A1/en active Pending
-
2022
- 2022-09-09 US US17/941,589 patent/US20230026686A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11464810B2 (en) | 2022-10-11 |
EP3503903A4 (fr) | 2020-03-25 |
EP3503903A1 (fr) | 2019-07-03 |
WO2018039593A9 (fr) | 2018-05-03 |
WO2018039593A1 (fr) | 2018-03-01 |
CN109843309A (zh) | 2019-06-04 |
EP3503904A1 (fr) | 2019-07-03 |
MA46061A (fr) | 2019-07-03 |
US20190192578A1 (en) | 2019-06-27 |
WO2018039591A1 (fr) | 2018-03-01 |
US20190175663A1 (en) | 2019-06-13 |
US11077151B2 (en) | 2021-08-03 |
US20230026686A1 (en) | 2023-01-26 |
EP3503904A4 (fr) | 2020-03-25 |
US20220016182A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45192A (fr) | Traitement d'association | |
MA46062A (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
DK3515946T5 (da) | Anti-MUC16-(MUCIN 16)-antistoffer | |
DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
FR3036037B1 (fr) | Harnais d'encordement perfectionne | |
FIC20240013I1 (fi) | Lebrikitsumabi | |
FR3039372B1 (fr) | Dispositif de traitement de la chevelure | |
DK3463269T3 (da) | Hånddesinfektionsmiddel | |
MA46717A (fr) | Variantes de l'endonucléase homing tcra | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA47408A (fr) | Traitement du cancer | |
FR3036591B1 (fr) | Dispositif de traitement de la chevelure | |
ES2893126T8 (es) | Métodos de tratamiento de afecciones oculares | |
MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
DK3294769T3 (da) | Behandling for multipelt myelom (mm) | |
DK3451886T3 (da) | Gulvbehandlingssystem | |
DK3407909T3 (da) | Cancerbehandling | |
ITUA20163694A1 (it) | "ciclocomputer con dispositivo di elaborazione delle immagini" | |
MA49744A (fr) | Méthodes de traitement de l'oesophagite à éosinophiles active | |
FR3053129B1 (fr) | Microscope | |
ITUA20163609A1 (it) | "micro-cogeneratore". | |
ITUA20162490A1 (it) | Attuatore per esoscheletro | |
FI11931U1 (fi) | Järjestely vesikaton läpiviennin pellittämiseksi |